Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-054228
Filing Date
2021-11-04
Accepted
2021-11-04 07:04:07
Documents
58
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20210930.htm   iXBRL 10-Q 3110088
2 EX-31.1 agle-ex311_8.htm EX-31.1 16034
3 EX-31.2 agle-ex312_6.htm EX-31.2 15979
4 EX-32.1 agle-ex321_7.htm EX-32.1 7055
5 EX-32.2 agle-ex322_9.htm EX-32.2 6986
  Complete submission text file 0001564590-21-054228.txt   8793795

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA agle-20210930.xsd EX-101.SCH 42394
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20210930_cal.xml EX-101.CAL 45346
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20210930_def.xml EX-101.DEF 134637
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20210930_lab.xml EX-101.LAB 333779
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20210930_pre.xml EX-101.PRE 251174
11 EXTRACTED XBRL INSTANCE DOCUMENT agle-10q_20210930_htm.xml XML 1675294
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 211377948
SIC: 2834 Pharmaceutical Preparations